Fulgent Genetics, Inc.
NASDAQ:FLGT
22.89 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 289.213 | 618.968 | 992.584 | 421.712 | 32.528 | 21.357 | 18.73 | 18.276 | 9.576 | 1.278 | 0 |
| Cost of Revenue
| 192.602 | 252.067 | 215.533 | 89.807 | 14.107 | 10.692 | 8.551 | 6.721 | 5.069 | 0.936 | 0 |
| Gross Profit
| 96.611 | 366.901 | 777.051 | 331.905 | 18.421 | 10.665 | 10.179 | 11.555 | 4.507 | 0.342 | 0 |
| Gross Profit Ratio
| 0.334 | 0.593 | 0.783 | 0.787 | 0.566 | 0.499 | 0.543 | 0.632 | 0.471 | 0.268 | 0 |
| Reseach & Development Expenses
| 41.44 | 28.91 | 24.219 | 11.58 | 6.537 | 5.534 | 4.223 | 3.558 | 4.431 | 0.521 | 0 |
| General & Administrative Expenses
| 88.999 | 111.074 | 50.732 | 15.215 | 6.414 | 5.537 | 5.133 | 4.609 | 2.418 | 0.23 | 0 |
| Selling & Marketing Expenses
| 41.467 | 38.918 | 24.439 | 14.952 | 5.898 | 4.651 | 4.223 | 2.469 | 2.67 | 0.581 | 0 |
| SG&A
| 130.466 | 149.992 | 75.171 | 30.167 | 12.312 | 10.188 | 9.356 | 7.078 | 5.088 | 0.811 | 0 |
| Other Expenses
| 0 | 6.497 | 1.708 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 104.339 |
| Operating Expenses
| 171.906 | 185.399 | 101.098 | 41.747 | 18.849 | 15.722 | 13.579 | 10.636 | 9.519 | 1.332 | 104.339 |
| Operating Income
| -75.295 | 178.527 | 675.953 | 290.158 | -0.428 | -5.057 | -3.4 | 0.919 | -5.012 | -0.99 | 104.339 |
| Operating Income Ratio
| -0.26 | 0.288 | 0.681 | 0.688 | -0.013 | -0.237 | -0.182 | 0.05 | -0.523 | -0.775 | 0 |
| Total Other Income Expenses Net
| -98.79 | 5.498 | 1.347 | 1.526 | 0.837 | 0.434 | 0.481 | -5.386 | 0.027 | 0 | 0 |
| Income Before Tax
| -174.085 | 184.025 | 677.3 | 291.684 | 0.409 | -4.623 | -2.919 | -4.468 | -4.985 | -0.99 | 104.339 |
| Income Before Tax Ratio
| -0.602 | 0.297 | 0.682 | 0.692 | 0.013 | -0.216 | -0.156 | -0.244 | -0.521 | -0.775 | 0 |
| Income Tax Expense
| 1.154 | 42.102 | 174.795 | 72.532 | 0.043 | -1.069 | -0.768 | 0.92 | 3.329 | 3.293 | 0 |
| Net Income
| -167.825 | 143.403 | 507.364 | 214.31 | 0.366 | -4.489 | -2.661 | -5.388 | -8.314 | -4.283 | 104.339 |
| Net Income Ratio
| -0.58 | 0.232 | 0.511 | 0.508 | 0.011 | -0.21 | -0.142 | -0.295 | -0.868 | -3.351 | 0 |
| EPS
| -5.63 | 4.76 | 17.13 | 9.64 | 0.02 | -0.25 | -0.15 | -0.3 | -0.65 | -0.34 | 3.48 |
| EPS Diluted
| -5.63 | 4.63 | 16.26 | 9.09 | 0.02 | -0.25 | -0.15 | -0.3 | -0.65 | -0.34 | 3.34 |
| EBITDA
| -43.538 | 190.974 | 677.661 | 290.158 | -0.428 | -5.057 | -3.4 | 0.919 | -4.437 | -0.794 | 104.339 |
| EBITDA Ratio
| -0.151 | 0.309 | 0.683 | 0.688 | -0.013 | -0.237 | -0.182 | 0.05 | -0.463 | -0.621 | 0 |